This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS eyes growth on value-based care surge and FME25+ savings, but regulatory headwinds, flat volumes and China weakness cloud outlook.
ISRGNegative Net Change CAHPositive Net Change FMSPositive Net Change PAHCPositive Net Change
medical medical-devices
BTSG Growth Drivers in 2026 Across Specialty and Providers
by Indrajit Bandyopadhyay
BTSG leans on specialty and provider growth in 2026, with margin expansion expected to outpace revenue despite near-term pharmacy headwinds.
CVSPositive Net Change OPCHPositive Net Change BTSGNegative Net Change
medical medical-devices
Is BrightSpring BTSG Stock Expensive at 24.5x Forward P/E?
by Indrajit Bandyopadhyay
BTSG trades at 24.5x forward earnings after strong 2025 results, but 2026 hinges on margin gains offsetting policy-driven revenue headwinds.
CVSPositive Net Change OPCHPositive Net Change BTSGNegative Net Change
medical medical-devices
BTSG and the Shift to Home Care as Margins Expand in 2026
by Indrajit Bandyopadhyay
BTSG targets margin expansion in 2026 as home-care demand grows, but policy and pricing pressures could cloud revenue trends.
ADUSPositive Net Change OPCHPositive Net Change BTSGNegative Net Change
medical medical-devices
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.
ISRGNegative Net Change CAHPositive Net Change PAHCPositive Net Change TMDXNegative Net Change
medical medical-devices
HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?
by Moumi Mondal
Align Technology's growth surges on record aligner demand and DSO expansion, while Hologic's near-complete buyout leaves little upside for investors.
ALGNNegative Net Change HOLXNo Net Change
medical medical-devices
Is Zimmer Biomet Stock the Right Pick for Your Portfolio Now?
by Zacks Equity Research
ZBH leans on knee growth, robotics innovation and steady markets, but debt levels and stiff competition complicate its near-term investment appeal.
ISRGNegative Net Change GMEDNegative Net Change PAHCPositive Net Change ZBHPositive Net Change
medical medical-devices
Here's Why You Should Retain GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare rides a strong backlog, innovation and diagnostics growth, but tariffs and margin pressures threaten to temper its forward momentum.
ISRGNegative Net Change CAHPositive Net Change PAHCPositive Net Change GEHCNegative Net Change
medical medical-devices
GE HealthCare Wins FDA 510(k) Clearance for Photonova Spectra PCCT
by Zacks Equity Research
GEHC gains FDA nod for Photonova Spectra, a next-gen photon-counting CT system to boost diagnostic precision, workflow efficiency and imaging insights.
ISRGNegative Net Change CAHPositive Net Change PAHCPositive Net Change GEHCNegative Net Change
medical medical-devices
The Longevity Economy: Why Healthcare REITs Are in Focus
by Urmimala Biswas
Ventas highlights how aging demographics are boosting healthcare REIT demand, with senior housing occupancy growth and limited supply supporting long-term growth.
VTRPositive Net Change OHIPositive Net Change CTREPositive Net Change WELLPositive Net Change
finance healthcare housing medical medical-devices real-estate